Search Results

Should you get both vaccinations? Yes, says an infectious disease doctor with the U.S. National Foundation for Infectious Diseases.

https://www.csl.com/we-are-csl/vita-original-stories/2021/protecting-yourself-from-covid-19-and-influenza

The agreement grants access to Arcturus Therapeutics' late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology, which recently reported results from a large COVID-19 Phase III vaccine efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favorable safety and tolerability profile.

https://newsroom.csl.com/2022-12-12-CSL-Announces-Closing-of-Global-Collaboration-and-Licensing-Agreement-with-Arcturus-Therapeutics

If you're immunocompro- mised, you won't be the one caring for a child with the flu or COVID-19.

https://www.csl.com/-/media/csl/more-than-a-patient-book/more-than-a-patient-by-jodi-taub.pdf

By securing access to these flu vaccines, if a pandemic is declared by the WHO, we are reinforcing our commitment to protecting health and being prepared and ready to act in the face of emerging public health threats" commented The Honourable Marjorie Michel, Minister of Health.

https://newsroom.csl.com/2026-03-05-Canada-and-CSL-Seqirus,-a-Global-Leader-in-Influenza-Vaccines,-agree-on-new-Pandemic-Preparedness-Contract

It has developed a COVID-19 vaccine candidate and has recently reported results from a large Phase III vaccine efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favorable safety and tolerability profile.

https://newsroom.csl.com/2022-11-01-CSL-Enters-Licensing-Agreement-with-Arcturus-Therapeutics-for-Next-Generation-mRNA-Vaccine-Technology

At CSL Seqirus, we're privileged to partner with more than 30 governments worldwide to help protect populations from emerging pandemic threats," said Ray Longstaff, CSL Seqirus, Director for Pandemic & Outbreak Preparedness and Response.

https://newsroom.csl.com/2025-04-29-CSL-Seqirus,-a-Global-Leader-in-Pandemic-Preparedness-and-Outbreak-Response,-Signs-an-Agreement-with-the-European-Commission-to-Support-Pandemic-Preparedness-Plans

Alpha 1 Antitrypsin (AAT) Deficiency is a genetic condition which can affect the lungs and liver. Learn more about this condition and what it means for patients.

https://www.csl.com/patients-public-health/rare-and-serious-diseases/alpha-1-antitrypsin-deficiency

As a clinician, I look forward to being able to provide a new treatment option that may help patients treated with HEMGENIX become free from the regular infusion schedule that many people living with hemophilia B rely on to protect them from the debilitating effects of the condition.

https://newsroom.csl.com/2022-11-22-U-S-Food-and-Drug-Administration-approves-CSLs-HEMGENIX-R-etranacogene-dezaparvovec-drlb-,-the-first-gene-therapy-for-hemophilia-B

CSL respectCSL to Seqirus the CSL UK Group's own and CSL manufacture Seqirus thepandemic differentiated preparedness, includingSeqirus is focused acrosson developing all age groups differentiated in expanded vaccines ® operations.product CSL FLUAD Seqirus, which has corporateis an adjuvanted the product UK, Canada, for the elderlySwitzerland protecting and againstmarkets respiratory is a viruses,strategic influenza priority forand CSL COVID-19 hubsmarket.

https://www.csl.com/-/media/one-csl/sustainability/data-and-reporting-centre/documents/csl-limited-tax-transparency-report-2024-25.pdf

From April 24-30, public health officials raise awareness about the protection vaccines provide and their potential to improve global health. This year, the World Health Organization (WHO) celebrates 50 years of its Expanded Programme on Immunization.

https://www.csl.com/we-are-csl/vita-original-stories/2024/world-immunization-week-2024